Unlocking Hope for Cancer Patients Using PDT
20
20
TUMOUR REGRESSION IN VIVO
SIGNIFICANT REGRESSION ON MULTIPLE TUMOUR TYPES
•
•
.
INV043 was used to treat implanted T-cell lymphoma, breast and pancreatic cancers in vivo
Low dose (0.1 mg/kg) administered by intra-tumoral injection and laser light applied after 1.5 hours.
Treated twice over a 24 hour period. Control animals received either laser or INV043 alone. Tumours
measured for 1 week following treatment to assess change in tumour size
Significant tumour regression was achieved in all cases
A.
T-cell Lymphoma
600]
% tumour size change
400
200
5001
400-
300-
200-
100
% tumour size change
0
2
み
6
days post-treatment
- Treated
- Control
Triple Negative Breast Cancer
0
2
4
days post-treatment
B.
% tumour size change
T-cell
Lymphoma
- Treated
- Control
Breast
Cancer
Pancreatic
6
8
Cancer
Pancreatic cancer
1500
1000
500
- Treated
- Control
0
2
4
6
8
days post-treatment
Pre-treatment
Day 0
Day 2
Day 4
Day 6
Control
Pre-treatment
Day 0
Day 2
Day 4
Day 6
Control
(A) All tumour types regressed
following treatment, as
determined by decrease in
measurable volume. Significant
reduction in tumour volume was
recorded for all treated mice
relative to untreated controls
(B) Immediately following laser
activation tumour tissue became
less palpable and developed a
"bruised" appearance. Necrosis
of tumour evident within 2 days
as a distinct darkening of tumour
mass beneath the skin. Followed
by formation of a visible eschar
in all cases after 2-4 days. Neither
laser nor INV043 alone had any
measurable effect
(n=4-8/group)
INVION
Pre-treatment
Day 0
Day 2
Day 4
Day 6
ControlView entire presentation